Background: Hemophagocytic lymphohistiocytosis (HLH) is a rarely recognized hyperinflammatory condition of high death risk.
Objective: The objective was to describe a case of HLH in a patient with multiple sclerosis (MS) treated with ocrelizumab.
Methods: Clinical observation, laboratory testing, and use of HLH-2004 criteria for HLH diagnosis.